SCHEMBL20170926

SCHEMBL20170926

COCCCCOc1ccccc1N

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.69
CYP2C9 P11712 1/20 0.69
CYP2C19 P33261 1/20 0.69
ALDH1A1 P00352 4/20 0.59
TDP1 Q9NUW8 3/20 0.54
ADRA2B P18089 1/20 0.54
PTGS1 P23219 1/20 0.54
LMNA P02545 3/20 0.47
RECQL P46063 1/20 0.47
L3MBTL1 Q9Y468 4/20 0.46
APP P05067 1/20 0.44
KDM4E B2RXH2 3/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 2/20 0.42
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
PTK2B Q14289 1/20 0.42
NCF1 P14598 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ADRB2 P07550 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3066845 0.96 CYP1A2 (0.69) CYP1A2CYP2C9CYP2C19ALDH1A1TDP1
SCHEMBL1029928 0.90 CYP1A2 (0.66) CYP1A2CYP2C9CYP2C19ALDH1A1TDP1
SCHEMBL29684634 0.90 CYP1A2 (0.66) CYP1A2CYP2C9CYP2C19ALDH1A1TDP1
SCHEMBL10387995 0.89 CYP1A2 (0.76) CYP1A2CYP2C9CYP2C19ALDH1A1TDP1
SCHEMBL23493031 0.87 CYP1A2 (0.73) CYP1A2CYP2C9CYP2C19ALDH1A1TDP1
SCHEMBL10804708 0.87 CYP1A2 (0.73) CYP1A2CYP2C9CYP2C19ALDH1A1TDP1
SCHEMBL23493019 0.87 CYP1A2 (0.73) CYP1A2CYP2C9CYP2C19ALDH1A1TDP1
SCHEMBL3358175 0.87 CYP1A2 (0.73) CYP1A2CYP2C9CYP2C19ALDH1A1TDP1
SCHEMBL865680 0.87 CYP1A2 (0.73) CYP1A2CYP2C9CYP2C19ALDH1A1TDP1
SCHEMBL867259 0.87 CYP1A2 (0.73) CYP1A2CYP2C9CYP2C19ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970334-B1 MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES BIOGEN MA INC (US) 2018-05-23 EP disclosed